These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 36248912)

  • 1. Prognostic value of programmed cell death ligand-1 expression in patients with bladder urothelial carcinoma undergoing radical cystectomy: A meta-analysis.
    Zhang J; Song L; Zhu H; Liu Q; Wang D
    Front Immunol; 2022; 13():986911. PubMed ID: 36248912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy.
    Murakami Y; Matsumoto K; Shimizu Y; Ikeda M; Amano N; Shimura S; Ishii D; Sato Y; Iwamura M
    Urol Oncol; 2021 Mar; 39(3):195.e15-195.e23. PubMed ID: 33071109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy.
    Hwang EC; Sathianathen NJ; Imamura M; Kuntz GM; Risk MC; Dahm P
    Cochrane Database Syst Rev; 2019 May; 5(5):CD013336. PubMed ID: 31111956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
    Owyong M; Lotan Y; Kapur P; Panwar V; McKenzie T; Lee TK; Zi X; Martin JW; Mosbah A; Abol-Enein H; Ghoneim M; Youssef RF
    Urol Oncol; 2019 Jul; 37(7):478-484. PubMed ID: 30910351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.
    Xian F; Ren D; Bie J; Xu G
    Front Immunol; 2023; 14():1119168. PubMed ID: 37138876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effect on survival of pelvic lymph node dissection at radical cystectomy for muscle invasive bladder cancer.
    Larcher A; Sun M; Schiffmann J; Tian Z; Shariat SF; McCormack M; Saad F; Fossati N; Abdollah F; Briganti A; Buffi N; Graefen M; Guazzoni G; Montorsi F; Karakiewicz PI
    Eur J Surg Oncol; 2015 Mar; 41(3):353-60. PubMed ID: 25477269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial.
    Basile G; Bandini M; Gibb EA; Ross JS; Raggi D; Marandino L; Costa de Padua T; Crupi E; Colombo R; Colecchia M; Lucianò R; Nocera L; Moschini M; Briganti A; Montorsi F; Necchi A
    Clin Cancer Res; 2022 Dec; 28(23):5107-5114. PubMed ID: 36190522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
    de Jong JJ; Stoop H; Nieboer D; Boormans JL; van Leenders GJLH
    Histopathology; 2018 Dec; 73(6):983-989. PubMed ID: 30003574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends of Lymph Node Outcomes in Partial Cystectomy for Muscle-Invasive Urothelial Carcinoma of the Bladder.
    Klose C; Gordon O; Sparks A; Whalen M
    Clin Genitourin Cancer; 2023 Dec; 21(6):703-709. PubMed ID: 37336704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
    Vetterlein MW; Seisen T; May M; Nuhn P; Gierth M; Mayr R; Fritsche HM; Burger M; Novotny V; Froehner M; Wirth MP; Protzel C; Hakenberg OW; Roghmann F; Palisaar RJ; Noldus J; Pycha A; Bastian PJ; Trinh QD; Xylinas E; Shariat SF; Rink M; Chun FK; Dahlem R; Fisch M; Aziz A;
    Eur Urol Focus; 2018 Mar; 4(2):252-259. PubMed ID: 28753775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laparoscopic pelvic lymph node dissection system based on preoperative primary tumour stage (T stage) by computed tomography in urothelial bladder cancer: results of a single-institution prospective study.
    Yuan JB; Zu XB; Miao JG; Wang J; Chen MF; Qi L
    BJU Int; 2013 Jul; 112(2):E87-91. PubMed ID: 23323729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity.
    Tarin TV; Power NE; Ehdaie B; Sfakianos JP; Silberstein JL; Savage CJ; Sjoberg D; Dalbagni G; Bochner BH
    Eur Urol; 2012 May; 61(5):1025-30. PubMed ID: 22342773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks and benefits of pelvic lymphadenectomy in octogenarians undergoing radical cystectomy due to urothelial carcinoma of the bladder.
    Grabbert M; Grimm T; Buchner A; Kretschmer A; Apfelbeck M; Schulz G; Jokisch F; Schneevoigt BS; Stief CG; Karl A
    Int Urol Nephrol; 2017 Dec; 49(12):2137-2142. PubMed ID: 28900840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
    Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
    J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pelvic lymphadenectomy: Evaluating nodal stage migration and will rogers effect in bladder cancer.
    Sodagum L; Passarelli R; Pfail J; Patel HV; Chua K; Doppalapudi SK; Golombos D; Elsamra SE; Singer EA; Jang TL; Srivastava A; Ghodoussipour S
    Urol Oncol; 2024 Jan; 42(1):21.e9-21.e20. PubMed ID: 37953186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes.
    Mistretta FA; Cyr SJ; Luzzago S; Mazzone E; Knipper S; Palumbo C; Tian Z; Nazzani S; Saad F; Montanari E; Tilki D; Briganti A; Shariat SF; de Cobelli O; Karakiewicz PI
    Clin Genitourin Cancer; 2020 Apr; 18(2):129-137.e3. PubMed ID: 32001182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
    Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
    Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
    Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
    Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.
    Ma B; Li H; Zhang C; Yang K; Qiao B; Zhang Z; Xu Y
    Eur J Surg Oncol; 2013 Oct; 39(10):1150-6. PubMed ID: 23721764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
    Rizzo A; Mollica V; Massari F
    Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.